gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Insulin-like growth factor 2 mRNA binding protein 3

IMP3, CT98
The protein encoded by this gene is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. The encoded protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism. A pseudogene exists on chromosome 7, and there are putative pseudogenes on other chromosomes. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Insulin, CAN, HAD, p53, Insulin-Like Growth Factor II
Papers on IMP3
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Ligato et al., Hartford, United States. In Appl Immunohistochem Mol Morphol, Feb 2016
CONTEXT: α-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).
Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
Takeshima et al., Hiroshima, Japan. In Pathobiology, Feb 2016
Immunohistochemical staining and statistical analysis of Noxa expression in 81 cases of EM and 55 cases of RMH were performed and compared with the utility of other previously reported antibodies such as Desmin, EMA, GLUT-1, IMP-3 and CD146.
Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Naito et al., Tokyo, Japan. In Int J Oncol, Feb 2016
Insulin-like growth factor 2 mRNA-binding protein-3 (IGF2BP3, also known as IMP3) is thought of as a bona fide oncofetal protein, which is overexpressed and is involved in cell proliferation, migration, and invasion in several kinds of tumors.
Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Hiroshima et al., Tokorozawa, Japan. In J Clin Pathol, Feb 2016
METHODS: To help differentiate PMM from PPSC and RMH, we used immunohistochemistry to examine mesothelial-associated markers (calretinin, AE1/AE3, CK5/6, CAM5.2, D2-40, WT-1, HBME1, thrombomodulin), adenocarcinoma-associated markers (CEA, BerEP4, MOC31, ER (estrogen receptor), PgR, TTF-1, Claudin-4, Pax8), and malignant-related and benign-related markers (epithelial membrane antigen (EMA), desmin, GLUT-1, CD146 and IMP3), and FISH to examine for homozygous deletion of 9p21.
Practical issues in the diagnosis of serous carcinoma of the endometrium.
Matias-Guiu et al., Lleida, Spain. In Mod Pathol, Jan 2016
Although there is not a single immunohistochemical marker for distinguishing SC from its mimickers, some antibodies are useful (p53, p16, IMP2, and IMP3), particularly when used in combination.
Nestin: A biomarker of aggressive uterine cancers.
Syed et al., Bethesda, United States. In Gynecol Oncol, Jan 2016
Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3.
Urachal carcinoma of the bladder - impact of clinical and immunohistochemical parameters on patients' prognosis.
Vom Dorp et al., Essen, Germany. In J Urol, Jan 2016
The aim of this study was to explore the expression and prognostic relevance of six selected protein markers in UrC (p53, Ki67, RHAMM, BGN, IMP3 and MMP-7), which were formerly shown to be prognostic in urothelial carcinoma and colorectal adenocarcinoma.
IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.
Zhao et al., Guangzhou, China. In Lung, Dec 2015
PURPOSE: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein associated with several aggressive and advanced cancers.
IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage.
Zhao et al., Guangzhou, China. In Int J Clin Exp Pathol, 2014
IMP3 is associated with lymph node metastasis and TNM stage and is a good independent prognostic biomarker for colorectal cancer (CRC).
Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization.
Zhang et al., Jinan, China. In Plos One, 2014
These 100 cervical specimens were assessed for expression of insulin-like growth factor II messenger RNA (mRNA)-binding protein 3 (IMP3), targeting protein for xenopus kinesin-like protein 2 (TPX2), and programmed cell death-1 ligand-1 (PD-L1) using immunohistochemical staining.
Sensitivity of alternative testing for pancreaticobiliary cancer: a 10-y review of the literature.
Chokshi et al., Newark, United States. In J Surg Res, 2014
Meta-analysis was performed on the sensitivity of EUS-FNA (74.2%), fluorescence in situ hybridization (54.2%), immunostain of insulin-like growth factor 2 mRNA-binding Protein 3 (IMP3; 80.4%), IMP3 + cytology (86.4%),
Oncofetal protein IMP3, a new cancer biomarker.
Jiang et al., Worcester, United States. In Adv Anat Pathol, 2014
IMP3 is a member of a family of RNA-binding proteins that consists of IMP1, IMP2 and IMP3.
Clinical implications of current developments in genitourinary pathology.
Jiang et al., Worcester, United States. In Arch Pathol Lab Med, 2013
OBJECTIVE: To review 5 stories in genitourinary pathology: (1) fusion in the ETS (E26) gene family in prostatic adenocarcinoma; (2) insulin-like growth factor II messenger RNA-binding protein 3 (IMP3), an important prognostic biomarker for kidney and bladder cancers; (3) translocation renal cell carcinoma; (4) UroVysion fluorescence in situ hybridization test in urine cytology for detection of bladder cancer; and (5) the use of triple immunostaining for diagnosis of prostate cancer.
Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma.
Doki et al., Suita, Japan. In J Surg Oncol, 2012
Increased expression of IMP3 is correlated with peritoneal dissemination in gastric adenocarcinoma.
Yolk sac tumours revisited. A review of their many faces and names.
Nicolae et al., Granada, Spain. In Histopathology, 2012
Pluripotent antibodies (SALL4, Lin28, IMP-3) help in differential diagnoses, while some differentiation markers (CDX2, TTF-1, HepPar1) facilitate recognition of unusual variants of YSTs.
IMP3 immunocytochemical staining increases sensitivity in the routine cytologic evaluation of biliary brush specimens.
Ligato et al., Hartford, United States. In Diagn Cytopathol, 2012
The utility of combining routine Papanicolaou-stained cytologic evaluation with immunocytochemical expression of insulin-like growth factor mRNA-binding protein-3 (IMP3), was assessed.
The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis.
Zhou et al., Jinan, China. In J Mol Histol, 2012
IGF2 and IMP3 had different expression patterns, which might be associated with angiogenesis. However, cytoplasmic and nuclear expression of IGF2 and IMP3 might play different roles in the angiogenesis of osteosarcoma.
Analysis of IMP3 expression in prostate adenocarcinomas.
Sentürk et al., Denizli, Turkey. In Turk Patoloji Derg, 2011
Report IMP-3 plays no role in the malignant transformation of prostate adenocarcinomas.
IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
Peng et al., Guangzhou, China. In Chin Med J (engl), 2010
IMP3 may play an importent role in the carcinogenesis and tumor metastasis in gastric adenocarcinoma.
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
Wu et al., Worcester, United States. In Lancet Oncol, 2006
We aimed to investigate whether IMP3, an oncofetal RNA-binding protein, can be used as a biomarker to predict metastasis and prognosis of renal-cell carcinoma.
share on facebooktweetadd +1mail to friends